Previti Santo, Ettari Roberta, Calcaterra Elsa, Roggia Michele, Natale Benito, Weldert Annabelle C, Müller-Ruttloff Christin, Salisch Florian, Irto Anna, Cigala Rosalia Maria, Ziebuhr John, Schirmeister Tanja, Cosconati Sandro, Zappalà Maria
Department of Chemical, Biological, Pharmaceutical and Environmental Sciences, University of Messina, Viale Stagno d'Alcontres 31, 98166 Messina, Italy.
DiSTABiF, University of Campania Luigi Vanvitelli, Via Vivaldi 43, 81100 Caserta, Italy.
ACS Med Chem Lett. 2024 Mar 1;15(5):602-609. doi: 10.1021/acsmedchemlett.3c00562. eCollection 2024 May 9.
In this structure-activity relationship (SAR) study, we report the development of dual inhibitors with antiviral properties targeting the SARS-CoV-2 main protease (M) and human cathepsin L (hCatL). The novel molecules differ in the aliphatic amino acids at the P2 site and the fluorine position on the phenyl ring at the P3 site. The identified dual inhibitors showed values within 1.61 and 10.72 μM against SARS-CoV-2 M; meanwhile, values ranging from 0.004 to 0.701 μM toward hCatL were observed. A great interdependency between the nature of the side chain at the P2 site and the position of the fluorine atom was found. Three dual-targeting inhibitors exhibited antiviral activity in the low micromolar range with CC values >100 μM. Docking simulations were executed to gain a deeper understanding of the SAR profile. The findings herein collected should be taken into consideration for the future development of dual SARS-CoV-2 M/hCatL inhibitors.
在本构效关系(SAR)研究中,我们报告了针对严重急性呼吸综合征冠状病毒2(SARS-CoV-2)主要蛋白酶(M)和人组织蛋白酶L(hCatL)开发具有抗病毒特性的双重抑制剂。这些新型分子在P2位点的脂肪族氨基酸和P3位点苯环上的氟位置有所不同。所鉴定的双重抑制剂对SARS-CoV-2 M的IC₅₀值在1.61至10.72 μM范围内;同时,观察到对hCatL的IC₅₀值在0.004至0.701 μM之间。发现P2位点侧链的性质与氟原子的位置之间存在很大的相互依赖性。三种双靶点抑制剂在低微摩尔范围内表现出抗病毒活性,其CC₅₀值>100 μM。进行了对接模拟以更深入地了解构效关系概况。本文收集的研究结果应在双重SARS-CoV-2 M/hCatL抑制剂的未来开发中予以考虑。